Acute lymphoblastic leukaemia (ALL) - management overview
ALL · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
A malignancy of lymphoid precursors, the commonest childhood leukaemia but also seen in adults with poorer outcomes. Treatment uses prolonged multi-phase chemotherapy with CNS-directed therapy, targeted agents for Philadelphia-positive disease, and immunotherapy for relapse.
Red flags
- CNS involvement (cranial nerve palsy, headache)
- Tumour lysis syndrome
- Mediastinal mass with airway/SVC compromise (T-ALL)
- Neutropenic sepsis
- Hyperleukocytosis
Assessment
Differential diagnosis
- Acute myeloid leukaemia
- Lymphoblastic lymphoma
- Blast-phase CML
- Infectious mononucleosis / reactive lymphocytosis
- Aplastic anaemia
- Neuroblastoma (children)
Investigations
- FBC, film and blast count
- Bone marrow with immunophenotyping (B vs T lineage)
- Cytogenetics and molecular tests including BCR::ABL1 (Ph+)
- CSF examination for CNS involvement
- Tumour lysis labs and coagulation screen
- Testicular/imaging assessment and HLA typing
Management
- Recognise and admit urgently with supportive stabilisation
- Start tumour lysis prophylaxis and treat any sepsis
- Confirm diagnosis, lineage and genetic subtype including Philadelphia chromosome status
- Risk-stratify by age, white count, genetics and measurable residual disease
- Deliver multi-phase therapy: induction, consolidation, CNS-directed therapy, and prolonged maintenance
- Add a tyrosine kinase inhibitor to chemotherapy for Philadelphia-positive ALL
- Provide intrathecal chemotherapy +/- cranial irradiation for CNS prophylaxis
- Monitor measurable residual disease to guide intensification and transplant
- Use immunotherapy (blinatumomab, inotuzumab) and CAR-T for relapsed/refractory B-ALL
- Refer high-risk and relapsed disease for allogeneic transplant
Drugs & doses
Induction: vincristine 1.4 mg/m2 IV (cap 2 mg) weekly + corticosteroid (dexamethasone/prednisolone) + asparaginase + anthracycline
Imatinib 400-600 mg PO daily or dasatinib added for Philadelphia-positive ALL
Intrathecal methotrexate for CNS-directed therapy; 6-mercaptopurine + methotrexate maintenance
Blinatumomab IV continuous infusion / tisagenlecleucel CAR-T for relapsed B-ALL
Disposition
Immediate specialist admission; prolonged multidisciplinary protocol therapy; transplant/CAR-T referral for high-risk or relapsed disease.
Complications & pitfalls
- Tumour lysis syndrome
- Neutropenic sepsis
- CNS relapse
- Asparaginase toxicity (thrombosis, pancreatitis)
- Treatment-related late effects
- Relapse
Exam pearls
- Measurable residual disease is the strongest prognostic marker and steers therapy
- Philadelphia-positive ALL now responds well to chemotherapy plus a TKI
- CNS-directed therapy is essential - the CNS is a sanctuary site
- Immunotherapy and CAR-T have revolutionised relapsed B-ALL
- Paediatric-inspired protocols improve outcomes in younger adults
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.